• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
  • YouTube
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers
Home / Science / Technology

Technology

Technology

Unique strategy to develop allogeneic CAR T

Celyad Oncology is pioneering a differentiated approach to the discovery and development of allogeneic, or off-the-shelf, CAR T cell therapy candidates for the treatment of cancer led by a pair of non-gene edited approaches including our T-cell receptor Inhibitory Molecule (TIM) and short hairpin RNA (shRNA) technologies.

shRNA Platform - side banner

Celyad Oncology is advancing the field of allogeneic CAR T therapy by exploring two proprietary, non-gene edited technology platforms to target the TCR complex

Novel technology targeting the TCR underpins allogeneic CAR T cells.

In adoptive cell therapy, the infusion of donor-derived T cells to cancer patients with a different background then that of the donor leads to multiple reactions, including the donor cells attacking the patient’s healthy tissue, known as Graft-versus-Host disease (GvHD) as well as the rejection of the therapy by the patient’s immune system known as Host-versus-Graft (HvG) reaction.

The key molecule principally responsible for GvHD is the T cell receptor (TCR), a molecule present at the surface of T cells. At the center of allogeneic CAR T therapy, the goal is to eliminate or blunt the signaling of the TCR through engineering with a specific technology. By reducing the signaling of the TCR, the engineered allogeneic CAR T cells fail to recognize the patient’s healthy tissue as foreign leading to an absence of GvHD.

Celyad Oncology’s non-gene edited technologies TIM and shRNA offer this potential. Through the co-expression of either technology with specific CAR of interest, we can design cell therapy candidates intended to inhibit the function of the TCR while allowing the T cells to target the cancer. In addition, shRNA technology may also offer the potential to avoid HvG, allowing the CAR T cells to persist longer in the patient offering the opportunity for improved outcomes.

learn About Our TIM Technology

Footer

  • About
  • Science
  • Pipeline
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter
  • YouTube

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help us improve it by collecting statistics on how visitors use our website. By clicking on “I accept”, you allow us to place these analytics cookies. We also use cookies that are necessary for the good-functioning of our website. You can find more information about the cookies we use by visiting our Cookie Policy.I AcceptI RefuseCookie Policy